Symbols / TBPH
TBPH Chart
About
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 924.77M |
| Enterprise Value | 639.69M | Income | 29.34M | Sales | 80.33M |
| Book/sh | 4.59 | Cash/sh | 6.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | 97 | IPO | — |
| P/E | 32.02 | Forward P/E | 10.80 | PEG | — |
| P/S | 11.51 | P/B | 3.97 | P/C | — |
| EV/EBITDA | -20.53 | EV/Sales | 7.96 | Quick Ratio | 9.30 |
| Current Ratio | 9.48 | Debt/Eq | 19.17 | LT Debt/Eq | — |
| EPS (ttm) | 0.57 | EPS next Y | 1.69 | EPS Growth | — |
| Revenue Growth | 18.50% | Earnings | 2026-03-05 | ROA | -5.32% |
| ROE | 14.03% | ROIC | — | Gross Margin | 50.82% |
| Oper. Margin | -32.29% | Profit Margin | 36.53% | Shs Outstand | 50.67M |
| Shs Float | 23.45M | Short Float | 14.33% | Short Ratio | 12.28 |
| Short Interest | — | 52W High | 21.03 | 52W Low | 7.90 |
| Beta | 0.16 | Avg Volume | 455.82K | Volume | 1.18M |
| Target Price | $26.71 | Recom | Buy | Prev Close | $18.19 |
| Price | $18.25 | Change | 0.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$26.71
Mean price target
2. Current target
$18.25
Latest analyst target
3. DCF / Fair value
$3.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.25
Low
$13.00
High
$42.00
Mean
$26.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-03 | reit | BTIG | Buy → Buy | $40 |
| 2025-12-03 | init | Oppenheimer | — → Outperform | $27 |
| 2025-11-26 | main | BTIG | Buy → Buy | $40 |
| 2025-11-11 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-09-12 | init | B. Riley Securities | — → Buy | $28 |
| 2025-06-27 | main | BTIG | Buy → Buy | $25 |
| 2025-06-17 | init | Jones Trading | — → Buy | $24 |
| 2025-02-27 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-02-25 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-08-06 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-08-06 | main | TD Cowen | Hold → Hold | $9 |
| 2024-08-06 | down | Leerink Partners | Outperform → Market Perform | $10 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-04-12 | init | BTIG | — → Buy | $21 |
| 2023-08-08 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-05-09 | main | HC Wainwright & Co. | — → Buy | $20 |
| 2023-02-28 | reit | HC Wainwright & Co. | — → Buy | $19 |
| 2022-11-17 | main | SVB Leerink | — → Outperform | $14 |
- CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? - Yahoo Finance ue, 24 Feb 2026 13
- Tax withholding reduces Theravance (NASDAQ: TBPH) SVP Grimaud’s share count - Stock Titan Wed, 25 Feb 2026 00
- TBPH Technical Analysis & Stock Price Forecast - Intellectia AI Fri, 27 Feb 2026 18
- Understanding the Setup: (TBPH) and Scalable Risk - Stock Traders Daily Fri, 27 Feb 2026 15
- Hillsdale Investment Management Inc. Purchases New Position in Theravance Biopharma, Inc. $TBPH - MarketBeat Mon, 23 Feb 2026 10
- Insider Sale: Director at $TBPH Sells 29,500 Shares - Quiver Quantitative Fri, 14 Nov 2025 08
- Revenues Not Telling The Story For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Shares Rise 32% - simplywall.st Wed, 12 Nov 2025 08
- [Form 4] Theravance Biopharma, Inc. Insider Trading Activity - Stock Titan Wed, 25 Feb 2026 00
- Theravance Biopharma Inc (NASDAQ:TBPH) Shows Strong Technical and Fundamental Momentum - ChartMill Wed, 11 Feb 2026 08
- Here's Why Shares in Theravance Biopharma Exploded Today - The Motley Fool ue, 11 Nov 2025 08
- CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? - Yahoo Finance hu, 30 Oct 2025 07
- TBPH Should I Buy - Intellectia AI Fri, 20 Feb 2026 18
- Theravance Biopharma (TBPH) to Release Earnings on Wednesday - MarketBeat Wed, 18 Feb 2026 08
- Is Oppenheimer’s Focus on Ampreloxetine Quietly Redefining Theravance Biopharma’s (TBPH) Risk-Reward Profile? - simplywall.st hu, 04 Dec 2025 08
- Newtyn discloses 8.5% Theravance Biopharma (NASDAQ: TBPH) ownership stake - Stock Titan ue, 17 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 31067 | 582501 | — | Sale at price 18.75 per share. | FARNUM RHONDA | Officer | — | 2025-12-03 00:00:00 | D |
| 1 | 29501 | 590020 | — | Sale at price 20.00 per share. | BROSHY ERAN | Director | — | 2025-11-26 00:00:00 | D |
| 2 | 9900 | — | — | Stock Gift at price 0.00 per share. | WINNINGHAM RICK E | Chief Executive Officer | — | 2025-11-19 00:00:00 | D |
| 3 | 59000 | 1068250 | — | Sale at price 17.00 - 18.50 per share. | BROSHY ERAN | Director | — | 2025-11-11 00:00:00 | D |
| 4 | 45000 | 809250 | — | Sale at price 17.00 - 18.50 per share. | BROSHY ERAN | Director | — | 2025-11-11 00:00:00 | D |
| 5 | 14000 | 142100 | — | Conversion of Exercise of derivative security at price 10.15 per share. | BROSHY ERAN | Director | — | 2025-11-11 00:00:00 | D |
| 6 | 10000 | 113870 | — | Sale at price 11.39 per share. | FARNUM RHONDA | Officer | — | 2025-07-14 00:00:00 | D |
| 7 | 20000 | — | — | Stock Gift at price 0.00 per share. | WINNINGHAM RICK E | Chief Executive Officer | — | 2025-06-23 00:00:00 | D |
| 8 | 9600 | — | — | Stock Gift at price 0.00 per share. | WINNINGHAM RICK E | Chief Executive Officer | — | 2025-06-13 00:00:00 | D |
| 9 | 24000 | 264000 | — | Sale at price 11.00 per share. | FARNUM RHONDA | Officer | — | 2025-06-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -947.73K | -576.03K | -3.33M | -12.09K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -33.94M | -39.92M | -63.55M | -227.94M |
| TotalUnusualItems | -4.51M | -2.74M | -15.87M | -20.14M |
| TotalUnusualItemsExcludingGoodwill | -4.51M | -2.74M | -15.87M | -20.14M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -56.42M | -55.19M | -92.82M | -265.07M |
| ReconciledDepreciation | 3.62M | 4.26M | 7.02M | 8.60M |
| EBITDA | -38.45M | -42.66M | -79.42M | -248.08M |
| EBIT | -42.07M | -46.92M | -86.45M | -256.68M |
| NetInterestIncome | 2.33M | 6.77M | 2.18M | -7.44M |
| InterestExpense | 2.55M | 2.35M | 6.37M | 8.55M |
| InterestIncome | 4.88M | 9.12M | 8.54M | 1.11M |
| NormalizedIncome | -52.85M | -53.03M | -80.29M | -244.94M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -56.42M | -55.19M | 872.13M | -199.43M |
| TotalExpenses | 106.82M | 110.72M | 130.47M | 292.95M |
| TotalOperatingIncomeAsReported | -46.95M | -56.03M | -91.96M | -257.78M |
| DilutedAverageShares | 48.85M | 55.30M | 73.59M | 69.46M |
| BasicAverageShares | 48.85M | 55.30M | 73.59M | 69.46M |
| DilutedEPS | -1.15 | -1.00 | 11.85 | -2.87 |
| BasicEPS | -1.15 | -1.00 | 11.85 | -2.87 |
| DilutedNIAvailtoComStockholders | -56.42M | -55.19M | 872.13M | -199.43M |
| NetIncomeCommonStockholders | -56.42M | -55.19M | 872.13M | -199.43M |
| NetIncome | -56.42M | -55.19M | 872.13M | -199.43M |
| NetIncomeIncludingNoncontrollingInterests | -56.42M | -55.19M | 872.13M | -199.43M |
| NetIncomeDiscontinuousOperations | 0.00 | 964.96M | 65.64M | |
| NetIncomeContinuousOperations | -56.42M | -55.19M | -92.82M | -265.07M |
| TaxProvision | 11.80M | 5.92M | 9.00K | -151.00K |
| PretaxIncome | -44.61M | -49.27M | -92.81M | -265.22M |
| OtherIncomeExpense | -4.51M | -2.74M | -15.87M | -20.14M |
| SpecialIncomeCharges | -4.51M | -2.74M | -15.87M | -20.14M |
| OtherSpecialCharges | 3.03M | |||
| ImpairmentOfCapitalAssets | 4.51M | 0.00 | ||
| RestructuringAndMergernAcquisition | 0.00 | 2.74M | 12.84M | 20.14M |
| EarningsFromEquityInterest | 103.99M | |||
| NetNonOperatingInterestIncomeExpense | 2.33M | 6.77M | 2.18M | -7.44M |
| InterestExpenseNonOperating | 2.55M | 2.35M | 6.37M | 8.55M |
| InterestIncomeNonOperating | 4.88M | 9.12M | 8.54M | 1.11M |
| OperatingIncome | -42.44M | -53.29M | -79.12M | -237.64M |
| OperatingExpense | 106.82M | 110.72M | 130.47M | 292.95M |
| ResearchAndDevelopment | 37.64M | 40.62M | 63.39M | 193.66M |
| SellingGeneralAndAdministration | 69.17M | 70.09M | 67.07M | 99.30M |
| TotalRevenue | 64.38M | 57.42M | 51.35M | 55.31M |
| OperatingRevenue | 64.38M | 57.42M | 51.35M | 55.31M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 49.47M | 48.09M | 65.23M | 74.44M |
| ShareIssued | 49.47M | 48.09M | 65.23M | 74.44M |
| NetDebt | 526.38M | |||
| TotalDebt | 49.82M | 49.16M | 52.16M | 669.52M |
| TangibleBookValue | 175.54M | 213.00M | 441.80M | -338.57M |
| InvestedCapital | 175.54M | 213.00M | 441.80M | 277.76M |
| WorkingCapital | 128.98M | 108.77M | 324.75M | 191.28M |
| NetTangibleAssets | 175.54M | 213.00M | 441.80M | -338.57M |
| CapitalLeaseObligations | 49.82M | 49.16M | 52.16M | 53.18M |
| CommonStockEquity | 175.54M | 213.00M | 441.80M | -338.57M |
| TotalCapitalization | 175.54M | 213.00M | 441.80M | 260.82M |
| TotalEquityGrossMinorityInterest | 175.54M | 213.00M | 441.80M | -338.57M |
| StockholdersEquity | 175.54M | 213.00M | 441.80M | -338.57M |
| GainsLossesNotAffectingRetainedEarnings | 7.00K | -65.00K | -15.00K | 0.00 |
| OtherEquityAdjustments | 7.00K | -65.00K | -15.00K | |
| RetainedEarnings | -965.52M | -909.10M | -853.91M | -1.73B |
| AdditionalPaidInCapital | 1.14B | 1.12B | 1.30B | 1.39B |
| CapitalStock | 0.00 | 0.00 | 1.00K | 1.00K |
| CommonStock | 0.00 | 0.00 | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 178.62M | 169.00M | 165.60M | 713.39M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 146.53M | 144.24M | 136.88M | 654.80M |
| OtherNonCurrentLiabilities | 32.22M | 33.71M | 27.09M | 2.18M |
| TradeandOtherPayablesNonCurrent | 75.20M | 65.29M | 64.19M | 240.00K |
| NonCurrentDeferredLiabilities | 0.00 | 192.00K | 310.00K | |
| NonCurrentDeferredRevenue | 0.00 | 192.00K | 310.00K | |
| LongTermDebtAndCapitalLeaseObligation | 39.11M | 45.24M | 45.41M | 652.08M |
| LongTermCapitalLeaseObligation | 39.11M | 45.24M | 45.41M | 52.68M |
| LongTermDebt | 599.39M | |||
| CurrentLiabilities | 32.09M | 24.77M | 28.71M | 58.59M |
| CurrentDeferredLiabilities | 24.00K | 98.00K | ||
| CurrentDeferredRevenue | 24.00K | 98.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 10.71M | 3.92M | 6.75M | 17.44M |
| CurrentCapitalLeaseObligation | 10.71M | 3.92M | 6.75M | 503.00K |
| CurrentDebt | 16.94M | |||
| OtherCurrentBorrowings | 16.94M | |||
| PayablesAndAccruedExpenses | 21.37M | 20.84M | 21.96M | 41.05M |
| CurrentAccruedExpenses | 13.28M | 12.83M | 20.41M | 37.95M |
| InterestPayable | 0.00 | 3.94M | ||
| Payables | 8.10M | 8.01M | 1.55M | 3.10M |
| OtherPayable | 6.49M | |||
| TotalTaxPayable | 5.85M | 0.00 | ||
| IncomeTaxPayable | 5.85M | 0.00 | ||
| AccountsPayable | 2.24M | 1.52M | 1.55M | 3.10M |
| TotalAssets | 354.16M | 382.00M | 607.40M | 374.82M |
| TotalNonCurrentAssets | 193.09M | 248.46M | 253.94M | 124.95M |
| OtherNonCurrentAssets | 157.32M | 203.10M | 201.94M | 4.07M |
| InvestmentsAndAdvances | 0.00 | 67.54M | ||
| LongTermEquityInvestment | 0.00 | 67.54M | ||
| NetPPE | 35.77M | 45.35M | 52.00M | 53.35M |
| AccumulatedDepreciation | -22.40M | -21.58M | -32.84M | -38.49M |
| GrossPPE | 58.17M | 66.94M | 84.84M | 91.84M |
| Leases | 25.32M | 26.21M | 24.58M | 24.05M |
| OtherProperties | 28.39M | 36.35M | 55.57M | 59.78M |
| MachineryFurnitureEquipment | 4.46M | 4.38M | 4.68M | 8.01M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 161.07M | 133.54M | 353.46M | 249.87M |
| OtherCurrentAssets | 4.20M | 11.60M | 7.68M | 8.56M |
| PrepaidAssets | 73.00K | 2.04M | 1.51M | 10.24M |
| Receivables | 68.44M | 17.47M | 16.79M | 57.60M |
| OtherReceivables | 50.00M | |||
| DuefromRelatedPartiesCurrent | 0.00 | 43.53M | ||
| AccountsReceivable | 18.44M | 17.47M | 16.79M | 14.06M |
| CashCashEquivalentsAndShortTermInvestments | 88.35M | 102.43M | 327.48M | 173.47M |
| OtherShortTermInvestments | 50.55M | 62.88M | 29.31M | 83.51M |
| CashAndCashEquivalents | 37.80M | 39.55M | 298.17M | 89.96M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -11.87M | -29.48M | -187.56M | -211.26M |
| RepurchaseOfCapitalStock | -3.10M | -199.55M | -132.28M | -9.06M |
| RepaymentOfDebt | 0.00 | -631.60M | -10.73M | |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 99.00K | 0.00 | 0.00 | 108.18M |
| CapitalExpenditure | -332.00K | -2.49M | -572.00K | -3.41M |
| InterestPaidSupplementalData | 0.00 | 22.24M | 39.03M | |
| IncomeTaxPaidSupplementalData | 109.00K | 24.00K | 117.97M | |
| EndCashPosition | 38.63M | 40.38M | 299.01M | 90.80M |
| BeginningCashPosition | 40.38M | 299.01M | 90.80M | 82.30M |
| ChangesInCash | -1.75M | -258.63M | 208.21M | 8.50M |
| FinancingCashFlow | -2.50M | -198.93M | -758.81M | 91.86M |
| CashFromDiscontinuedFinancingActivities | 0.00 | -20.19M | 0.00 | |
| CashFlowFromContinuingFinancingActivities | -2.50M | -198.93M | -738.62M | 91.86M |
| NetOtherFinancingCharges | 24.46M | |||
| ProceedsFromStockOptionExercised | 508.00K | 618.00K | 802.00K | 3.47M |
| NetCommonStockIssuance | -3.00M | -199.55M | -132.28M | 99.12M |
| CommonStockPayments | -3.10M | -199.55M | -132.28M | -9.06M |
| CommonStockIssuance | 99.00K | 0.00 | 0.00 | 108.18M |
| NetIssuancePaymentsOfDebt | 0.00 | -631.60M | -10.73M | |
| NetLongTermDebtIssuance | 0.00 | -631.60M | -10.73M | |
| LongTermDebtPayments | 0.00 | -631.60M | -10.73M | |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | 12.28M | -32.70M | 1.15B | 124.49M |
| CashFromDiscontinuedInvestingActivities | 0.00 | 1.10B | 0.00 | |
| CashFlowFromContinuingInvestingActivities | 12.28M | -32.70M | 58.88M | 124.49M |
| NetOtherInvestingChanges | 2.71M | |||
| NetInvestmentPurchaseAndSale | 12.62M | -31.72M | 54.87M | 127.89M |
| SaleOfInvestment | 155.65M | 102.81M | 158.02M | 286.20M |
| PurchaseOfInvestment | -143.03M | -134.53M | -103.14M | -158.31M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -332.00K | -975.00K | 1.29M | -3.40M |
| SaleOfPPE | 0.00 | 1.51M | 1.87M | 6.00K |
| PurchaseOfPPE | -332.00K | -2.49M | -572.00K | -3.41M |
| OperatingCashFlow | -11.54M | -27.00M | -186.99M | -207.86M |
| CashFromDiscontinuedOperatingActivities | 0.00 | -184.57M | 27.92M | |
| CashFlowFromContinuingOperatingActivities | -11.54M | -27.00M | -2.42M | -235.78M |
| ChangeInWorkingCapital | 20.36M | -8.34M | 42.35M | -39.55M |
| ChangeInOtherWorkingCapital | 9.91M | 886.00K | 63.76M | -11.65M |
| ChangeInOtherCurrentLiabilities | 129.00K | 4.55M | -1.55M | -965.00K |
| ChangeInOtherCurrentAssets | -296.00K | -1.55M | -8.23M | -972.00K |
| ChangeInPayablesAndAccruedExpense | 2.22M | -7.09M | -16.94M | -40.76M |
| ChangeInAccruedExpense | 1.47M | -7.09M | -15.33M | -37.23M |
| ChangeInInterestPayable | 0.00 | -1.25M | 0.00 | |
| ChangeInPayable | 750.00K | 6.00K | -1.61M | -3.53M |
| ChangeInAccountPayable | 750.00K | 6.00K | -1.61M | -3.53M |
| ChangeInPrepaidAssets | 9.36M | -4.45M | 8.03M | 13.00M |
| ChangeInReceivables | -966.00K | -689.00K | -2.72M | 1.80M |
| ChangesInAccountReceivables | -966.00K | -689.00K | -2.72M | 1.80M |
| OtherNonCashItems | 2.55M | 2.35M | 974.00K | -1.85M |
| StockBasedCompensation | 21.39M | 25.37M | 39.73M | 62.06M |
| AssetImpairmentCharge | 4.51M | 0.00 | ||
| DeferredTax | -7.57M | 3.21M | 0.00 | |
| DeferredIncomeTax | -7.57M | 3.21M | 0.00 | |
| DepreciationAmortizationDepletion | 3.62M | 4.26M | 7.02M | 8.60M |
| DepreciationAndAmortization | 3.62M | 4.26M | 7.02M | 8.60M |
| AmortizationCashFlow | -2.51M | -1.90M | -681.00K | 10.00K |
| AmortizationOfIntangibles | -2.51M | -1.90M | -681.00K | 10.00K |
| Depreciation | 6.12M | 6.15M | 7.71M | 8.59M |
| OperatingGainsLosses | 34.00K | 1.35M | 317.00K | 39.00K |
| EarningsLossesFromEquityInvestments | -44.52M | |||
| GainLossOnSaleOfPPE | 34.00K | 1.35M | -8.00K | 39.00K |
| NetIncomeFromContinuingOperations | -56.42M | -55.19M | -92.82M | -265.07M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TBPH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|